NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Paradigm and TME Research, a cancer physician network, announced today that they have signed a deal to launch a precision medicine breast cancer registry.

Under the arrangement, the so-called Paradigm Neoadjuvant Breast Registry will use Paradigm's PCDx next-generation sequencing-based test and other technologies to characterize the genomes and profile the tumors of invasive breast cancer patients with the goal of identifying the best pre-surgical treatment for each individual.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.